Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Combination Treatment Options for Castration-Resistant Prostate Cancer

Dannah R. Miller  1   2 , Matthew A. Ingersoll  1   3 , Benjamin A. Teply  4   5 , Ming-Fong Lin  1   5   6   7   8
Simon RJ Bott  1 , Keng Lim Ng  1
, editors.
In: Prostate Cancer [Internet]. Brisbane (AU): Exon Publications; 2021 May 27. Chapter 5.
Affiliations
Free Books & Documents
Review

Combination Treatment Options for Castration-Resistant Prostate Cancer

Dannah R. Miller et al.
Free Books & Documents

Excerpt

Prostate cancer is the most commonly diagnosed solid tumor and the second leading cause of cancer-related deaths in men in the United States. While localized prostate cancer has an excellent prognosis for patients, about one-third of patients are diagnosed with high-risk disease, including metastatic cancer. The 5-year survival rate of metastatic prostate cancer is only about 30%. Due to the androgen dependence of prostate cancer cells, androgen-deprivation therapy is the standard of care for metastatic prostate cancer, which includes both surgical and medical approaches. Nevertheless, androgen-deprivation therapy in general is not curative; patients can develop castration-resistant prostate cancer. Despite current chemotherapies, including the utilization of novel androgen signaling inhibitors and immunotherapy, patients still succumb to the disease. Hence, castration-resistant prostate cancer is a lethal disease. Combination treatment is a strategy for treating this lethal disease and thus will be the focus of discussion in this chapter.

PubMed Disclaimer

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590. - DOI - PubMed
    1. Mohler JL, Armstrong AJ, Bahnson RR, D’Amico AV, Davis BJ, Eastham JA, et al. Prostate Cancer, Version 1.2016. J Natl Compr Canc Netw. 2016;14(1):19–30. - PubMed
    1. McKay RR, Feng FY, Wang AY, Wallis CJD, Moses KA. Recent Advances in the Management of High-Risk Localized Prostate Cancer: Local Therapy, Systemic Therapy, and Biomarkers to Guide Treatment Decisions. Am Soc Clin Oncol Educ Book. 2020;40:1–12. https://doi.org/10.1200/EDBK_279459. - DOI - PMC - PubMed
    1. Huggins C, Clark PJ. Quantitative Studies of Prostatic Secretion : Ii. The Effect of Castration and of Estrogen Injection on the Normal and on the Hyperplastic Prostate Glands of Dogs. J Exp Med. 1940;72(6):747–62. https://doi.org/10.1084/jem.72.6.747. - DOI - PMC - PubMed
    1. Liu J, Geller J, Albert J, Kirshner M. Acute effects of testicular and adrenal cortical blockade on protein synthesis and dihydrotestosterone content of human prostate tissue. J Clin Endocrinol Metab. 1985;61(1):129–33. https://doi.org/10.1210/jcem-61-1-129. - DOI - PubMed

LinkOut - more resources